Clinical Trial Update: Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus [Phase 2]

View source ↗

Summary

A Phase 2 trial of gemcitabine for recurrent or refractory uterine cancer (uterine sarcoma) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Sarcoma

Drugs mentioned

• Gemcitabine (Gemzar) (gemcitabine)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Sarcoma | Phase 2 | Status: TERMINATED